H. Davies, G. R. Bignell, C. Cox, P. Stephens, S. Edkins et al., Mutations of the BRAF gene in human cancer, Nature. juin, vol.417, issue.6892, pp.949-54, 2002.

J. C. Jones, L. A. Renfro, A. Ho, A. B. Schrock, A. Rankin et al., Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer, J Clin Oncol Off J Am Soc Clin Oncol. 10 août, vol.35, issue.23, pp.2624-2654, 2017.

B. Tran, S. Kopetz, J. Tie, P. Gibbs, Z. Jiang et al., Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer, Cancer, vol.117, issue.20, pp.4623-4655, 2011.

J. Tie, P. Gibbs, L. Lipton, M. Christie, R. N. Jorissen et al., Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation, Int J Cancer. 1 mai, vol.128, issue.9, pp.2075-84, 2011.

W. Q. Li, K. Kawakami, A. Ruszkiewicz, G. Bennett, J. Moore et al., BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status, Mol Cancer. 10 janv, vol.5, issue.2, 2006.

J. Tol, I. D. Nagtegaal, and C. Punt, BRAF Mutation in Metastatic Colorectal Cancer, N Engl J Med. 2 juill, vol.361, issue.1, pp.98-107, 2009.

J. Souglakos, J. Philips, R. Wang, S. Marwah, M. Silver et al., Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer, Br J Cancer. août, vol.101, issue.3, pp.465-72, 2009.

F. Loupakis, C. Cremolini, G. Masi, S. Lonardi, V. Zagonel et al., Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer, N Engl J Med, vol.371, issue.17, pp.1609-1627, 2014.

F. Loupakis, C. Cremolini, L. Salvatore, G. Masi, E. Sensi et al., FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer, Eur J Cancer. janv, vol.50, issue.1, pp.57-63, 2014.

S. A. Forbes, G. Tang, N. Bindal, S. Bamford, D. E. Cole et al., COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer, Nucleic Acids Res. janv, vol.38, issue.suppl_1, pp.652-659, 2010.

J. Carter, L. Tseng, G. Zheng, J. Dudley, P. Illei et al., Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool, Am J Clin Pathol, vol.144, issue.4, pp.620-628, 2015.

F. Ciardiello, N. Normanno, E. Maiello, E. Martinelli, T. Troiani et al., Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by nextgeneration sequencing: findings from the CAPRI-GOIM trial, Ann Oncol. sept, vol.25, issue.9, pp.1756-61, 2014.

C. Cremolini, D. Bartolomeo, M. Amatu, A. Antoniotti, C. Moretto et al., BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis, Ann Oncol Off J Eur Soc Med Oncol, vol.26, issue.10, pp.2092-2099, 2015.

M. Amaki-takao, T. Yamaguchi, S. Natsume, T. Iijima, R. Wakaume et al., Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis, Oncology, vol.91, issue.3, pp.162-70, 2016.

M. G. Summers, C. G. Smith, T. S. Maughan, R. Kaplan, V. Escott-price et al., BRAF and NRAS Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer, Clin Cancer Res. 1 juin, vol.23, issue.11, pp.2742-2751, 2017.

T. Ikenoue, Y. Hikiba, F. Kanai, Y. Tanaka, J. Imamura et al., Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors, Cancer Res. 1 déc, vol.63, issue.23, pp.8132-8139, 2003.

P. Wan, M. J. Garnett, S. M. Roe, S. Lee, D. Niculescu-duvaz et al., Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF, Cell. 19 mars, vol.116, issue.6, pp.855-67, 2004.

Z. Yao, R. Yaeger, V. S. Rodrik-outmezguine, A. Tao, N. M. Torres et al., Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS, Nature, vol.10, issue.7666, pp.234-242, 2017.

E. Shinozaki, T. Yoshino, K. Yamazaki, K. Muro, K. Yamaguchi et al., Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study, Br J Cancer, vol.117, issue.10, pp.1450-1458, 2017.

G. Zheng, L. Tseng, G. Chen, L. Haley, P. Illei et al., Clinical detection and categorization of uncommon and concomitant mutations involving BRAF, BMC Cancer, vol.15, p.779, 2015.

J. Gong, M. Cho, M. Sy, R. Salgia, and M. Fakih, Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience, Oncotarget. 27 juin, vol.8, issue.26, pp.42198-213, 2017.

C. Cremolini, F. Loupakis, C. Antoniotti, C. Lupi, E. Sensi et al., FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study, Lancet Oncol, vol.16, issue.13, pp.1306-1321, 2015.

N. Hugen, R. H. Verhoeven, V. E. Lemmens, C. J. Van-aart, M. A. Elferink et al., Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor: Outcome and adjuvant chemotherapy in signet-ring cell carcinoma, Int J Cancer. 15 janv, vol.136, issue.2, pp.333-342, 2015.

M. Qiu, J. Hu, D. Yang, D. P. Cosgrove, and R. Xu, Pattern of distant metastases in colorectal cancer: a SEER based study, Oncotarget, issue.17, 2015.

A. P. Venook, D. Niedzwiecki, H. Lenz, F. Innocenti, B. Fruth et al., Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial, JAMA. 20 juin, vol.317, issue.23, p.2392, 2017.

J. Franko, Q. Shi, J. P. Meyers, T. S. Maughan, R. A. Adams et al., Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database, Lancet Oncol. déc, vol.17, issue.12, pp.1709-1728, 2016.

T. R. Van-oudheusden, L. G. Razenberg, Y. R. Van-gestel, G. J. Creemers, V. E. Lemmens et al., Systemic treatment of patients with metachronous peritoneal carcinomatosis of colorectal origin, vol.5, 2016.

J. B. Bachet, O. Bouché, J. Taieb, O. Dubreuil, M. L. Garcia et al., RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study, Ann Oncol. 1 mai, vol.29, issue.5, pp.1211-1220, 2018.

S. Venderbosch, I. D. Nagtegaal, T. S. Maughan, C. G. Smith, J. P. Cheadle et al., Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies, Clin Cancer Res, vol.20, issue.20, pp.5322-5352, 2014.

M. Koopman, G. Kortman, L. Mekenkamp, M. Ligtenberg, N. Hoogerbrugge et al., Deficient mismatch repair system in patients with sporadic advanced colorectal cancer, Br J Cancer. janv, vol.100, issue.2, pp.266-73, 2009.

Z. Yao, N. M. Torres, A. Tao, Y. Gao, L. Luo et al., BRAF Mutants Evade ERKDependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition, Cancer Cell. sept, vol.28, issue.3, pp.370-83, 2015.

V. Heinemann, L. F. Von-weikersthal, T. Decker, A. Kiani, U. Vehling-kaiser et al., FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, openlabel, Lancet Oncol. sept, vol.15, issue.10, pp.1065-75, 2014.

J. Bachet, N. Moreno-lopez, L. Viganò, U. Marchese, M. Gelli et al., What is the prognostic impact of BRAF mutation in patients undergoing resection of colorectal liver metastases? Results of nationwide intergroup (ACHBT, FRENCH, AGEO) cohort of 249 patients, J Clin Oncol. 20 mai, vol.36, issue.15_suppl, pp.3554-3554, 2018.

. Epidémiologie, pronostic et chimiosensibilité des mutations BRAF non V600E des adénocarcinomes colorectaux métastatiques RESUME Introduction : Les adénocarcinomes colorectaux métastatiques (CCRm) avec mutation BRAF non V600E sont rares (2,2%)

. Patients, Il s'agissait d'une cohorte multicentrique rétrospective française incluant les CCRm mutés BRAF non V600E, divisés en 3 groupes : prise en charge curative des métastases (groupe 1, n=35), chimiothérapie palliative (groupe 2, n=63)

, Leur localisation ainsi que leur dissémination métastatique étaient classiques. Il y avait surtout des adénocarcinomes bien et moyennement différenciés (88%). Les mutations BRAF les plus fréquentes, Résultats : Les 108 patients inclus avaient un âge médian au diagnostic métastatique de 66 ans, vol.21

, La chimiosensibilité était bonne avec 49,0% de réponse objective et 76,8% de taux de contrôle en 1 ère ligne dans les groupes 1 et 2. Les taux de réponse étaient semblables entre les antiEGFr et les antiVEGF. La médiane de survie globale (mSG), vol.105, p.1

, 16 mois et 8 mois. Il n'existait pas de différence de mSG en fonction du type de mutation (notamment pour D594 et K601) ni de l'impact fonctionnel sur BRAF

, Conclusion : Les CCRm mutés BRAF non V600E sont de bon pronostic, avec une bonne chimiosensibilité

, Mots clés : cancer colorectal, métastatique, mutation BRAF non V600E, pronostic, chimiosensibilité Epidemiology, prognosis and chemosensitivity of non-V600E BRAF mutations in metastatic colorectal adenocarcinoma